An oral drug combination by Swiss pharmaceuticals company Novartis (NOVN.S) showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.
https://www.pharmalive.com/wp-content/uploads/2022/06/ReutersNovartis6-6-2022.webp7951200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-06 08:11:112022-06-06 10:47:38Novartis drug combo shows promise in childhood brain cancer
